One-hundred days monitoring patients submitted to hematopoietic stem cell transplantation: Events of metabolic syndrome

Maria Cláudia Bernardes Spexoto, Maria Rita Marques de Oliveira

Resumo


Objective

This study assessed early manifestations of metabolic syndrome determinants in patients submitted to hematopoietic stem cell transplantation.

Methods

Twenty-seven individuals participated in the study (20 with autologous and 7 with allogeneic hematopoietic stem cell transplantation). Anthropometric variables and biochemical indicators of lipid and glucose metabolism were determined before and 100 days after hematopoietic stem cell transplantation.

Results

The mean total cholesterol (p=0.086), very low density lipoprotein-cholesterol (p=0.069) and triglycerides (p=0.086) of all patients did not change significantly between the two study periods, but when the patients were separated by type of hematopoietic stem cell transplantation, triglycerides and very low density lipoprotein-cholesterol were close to the critical level of significance for individuals with allogeneic hematopoietic stem cell transplantation (p=0.060) and total cholesterol was significant in individuals

with autologous hematopoietic stem cell transplantation (p=0.027). Anthropometric variables did not change significantly between before and 100 days after hematopoietic stem cell transplantation.

Conclusion

Metabolic syndrome risk factors may be associated with lipid metabolism in the early phase of allogeneic and autologous hematopoietic stem cell transplantation.

Indexing terms: Body composition. Hematopoietic stem cell transplantation. Lipids. Metabolic syndrome.


Palavras-chave


Body composition. Hematopoietic stem cell transplantation. Lipids. Metabolic syndrome.

Texto completo:

PDF

Referências


Annaloro C, Airaghi L, Saporiti G, Onida F, Cortelezzi

A, Deliliers GL. Metabolic syndrome in patients with

hematological diseases. Expert Rev Hematol. 2012;

(4):439-58.

Annaloro C, Onida F, Saporiti G, Lambertenghi

Deliliers G. Cancer stem cells in hematological

disorders: Current and possible new therapeutic

approaches. Curr Pharm Biotechnol. 2011;

(2):217-25.

Annaloro C, Usardi P, Airaghi L, Giunta V, Forti S,

Orsatti A, et al. Prevalence of metabolic syndrome in

long-term survivors of hematopoietic stem cell

transplantation. Bone Marrow Transplant. 2008;

(9):797-804.

Federation ID. The IDF consensus worldwide definition

of the metabolic syndrome. Belgium: International

Diabetes Federation; 2006.

Hildrum B, Mykletun A, Hole T, Midthjell K, Dahl AA.

Age-specific prevalence of the metabolic syndrome

defined by the International Diabetes Federation and

the National Cholesterol Education Program: The

Norwegian HUNT 2 study. BMC Public Health. 2007;

:220.

Lorenzo C, Serrano-Rios M, Martinez-Larrad MT,

Gonzalez-Sanchez JL, Seclen S, Villena A, et al.

Geographic variations of the International Diabetes

Federation and the National Cholesterol Education

Program-Adult Treatment Panel III definitions of the

metabolic syndrome in nondiabetic subjects. Diabetes

Care. 2006; 29(3):685-91.

Mannucci E, Monami M, Cresci B, Pala L, Bardini G,

Petracca MG, et al. National Cholesterol Education

Program and International Diabetes Federation

definitions of metabolic syndrome in the prediction

of diabetes. Results from the FIrenze-Bagno a Ripoli

study. Diabetes Obesity Metabol. 2008; 10(5):430-5.

Mertens I, Van Gaal LF. New International Diabetes

Federation (IDF) and National Cholesterol Education

Program Adult Treatment panel III (NCEP-ATPIII)

criteria and the involvement of hemostasis and

fibrinolysis in the metabolic syndrome. J Thrombosis

Haemostasis. 2006; 4(5):1164-6.

Nawabzad R, Champin B. [Concordance between

three definitions for metabolic syndrome

(Hypertriglyceridemic waist, National Cholesterol

Education Program, International Diabetes

Federation), and prevalence of the syndrome in a

French population]. Rev Prat. 2010; 60(10

Suppl):15-23.

Rezaianzadeh A, Namayandeh SM, Sadr SM. National

Cholesterol Education Program Adult Treatment Panel

III Versus International Diabetic Federation Definition

of Metabolic Syndrome, Which One is Associated with

Diabetes Mellitus and Coronary Artery Disease? Intern

J Preventive Medicine. 2012; 3(8):552-8.

Rodriguez A, Delgado-Cohen H, Reviriego J, Serrano-

-Rios M. Risk factors associated with metabolic

syndrome in type 2 diabetes Mellitus patients

according to World Health Organization, Third Report

National Cholesterol Education Program, and

International Diabetes Federation definitions.

Diabetes Metab Syndr Obes. 2011; 4:1-4.

Yoon YS, Lee ES, Park C, Lee S, Oh SW. The new

definition of metabolic syndrome by the international diabetes federation is less likely to identify

metabolically abnormal but non-obese individuals

than the definition by the revised national cholesterol

education program: The Korea NHANES study. Inter J

Obesity. 2007; 31(3):528-34.

Martin-Salces M, de Paz R, Canales MA, Mesejo A,

Hernandez-Navarro F. Nutritional recommendations

in hematopoietic stem cell transplantation. Nutrition.

; 24(7-8):769-75.

Majhail NS, Flowers ME, Ness KK, Jagasia M,

Carpenter PA, Arora M, et al. High prevalence of

metabolic syndrome after allogeneic hematopoietic

cell transplantation. Bone Marrow Transplan. 2009;

(1):49-54.

Baker KS, Armenian S, Bhatia S. Long-term

consequences of hematopoietic stem cell

transplantation: Current state of the science. Biol

Blood Marrow Transplant. 2010; 16(1 Suppl):S90-6.

Baker KS, Chow E, Steinberger J. Metabolic syndrome

and cardiovascular risk in survivors after

hematopoietic cell transplantation. Bone Marrow

Transplant. 2012; 47(5):619-25.

Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K,

Storek J, et al. Guidelines for preventing infectious

complications among hematopoietic cell

transplantation recipients: A global perspective. Biol

Blood Marrow Transplant. 2009; 15(10):1143-238.

Nagao K, Yanagita T. Bioactive lipids in metabolic

syndrome. Progress Lipid Res. 2008; 47(2):127-46.




DOI: https://doi.org/10.24220/2318-0897v23n1a2412

Apontamentos

  • Não há apontamentos.


Revista de Ciências Médicas

ISSNe 2318-0897 (eletrônico)
ISSN 1415-5796 (impresso)

Este site é melhor visualizado utilizando navegador gratuito Firefox.